Full-Time

Head of Regulatory Affairs

Updated on 4/17/2025

Azurity Pharmaceuticals

Azurity Pharmaceuticals

201-500 employees

Develops specialized formulations of medicines

No salary listed

Expert

Raleigh, NC, USA

Hybrid work model: 2 days from home and 3 days in the office.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • MD, PhD or PharmD in a scientific discipline preferred along with 15+ years of experience in Regulatory Affairs
  • Proven success in regulatory submissions
  • FDA, EU, Canada, ROW, and post-marketing experience is a plus with sound knowledge of such principles as GxP's, FDA, and EU guidelines
  • Previous experience in attending and leading a team to prepare for major health authority interactions (e.g. FDA pre-NDA/BLA, EOP2 meetings, advisory committee meetings and/or EU oral explanations/scientific advice, etc.)
  • Experience with investigational drugs, including late stage development, and marketed products
  • CRO management experience preferred
  • Prior managerial experience, with direct supervision of mid- to senior-level regulatory professionals, is highly desirable
  • Must be a strong leader that creates a vision for group
  • Must be strong overall and able to train/develop staff in the area of regulatory strategy such as understanding broad concepts within regulatory affairs and implications across the organization and globally; proactively identifies regulatory issues; offers creative solutions and strategies, including risk mitigation strategies
  • Strategic thinker, planner, and implementer with excellent organizational skills
  • Excellent oral and written communication skills and knows how to present data/issues both to a technical and non-technical audience with the ability to write and edit regulatory documents
  • Able to plan and execute regulatory projects, and proven record of delivering results within business-defined timeframes
  • Proven ability to work on complex problems where analysis of the situation or data requires an evaluation of intangible variables
  • Demonstrates potential for a high level of collaboration with others and within global teams
  • Independent thought, negotiation skills, integrity, and adaptability
  • Ability to work on own and in virtual setting
  • MS Office skills with excellent use of excel, PowerPoint and MS Project required
  • Fluent in English (written and oral)
Responsibilities
  • Oversees regional regulatory leads and staff responsible for ensuring global/regional regulatory strategies are written, reviewed, and executed according to plan
  • Provides strategic and tactical advice and guidance to allow the timely and efficient conduct of all regulatory projects
  • Ensures compliance for global regulatory requirements
  • Is a leader, contributing to cross-functional initiatives and influencing as applicable and demonstrating leadership behaviors
  • Directs and oversees multiple projects (inclusive of highly complex ones), generally has global/regional oversight for assigned products
  • Oversees and accountable for working with other RA functions and/or vendor to ensure that regulatory submissions and approvals are achieved on schedule within area of responsibility
  • Understands importance of regulatory documents for value and access discussions and partners with access functions to support access applications
  • Provides leadership and development for direct reports, including those that serve as regional regulatory leads responsible for the design and execution of regional regulatory strategies
  • Ensures project team colleagues, line management, and key stakeholders are apprised of developments that may impact regulatory success, exercising sound judgement and communicating in a professional and timely manner
  • Demonstrates ability to anticipate risks and responsible for developing solutions to identified risks and discussing with team and management; understands probabilities of technical success for the solutions
  • Accountable for all global submissions and approvals of project(s) and/or oversees direct reports responsible
  • Oversees all submissions
  • Leads and manages meetings and / or interactions with regulatory authorities and agency meetings; or delegates and oversees direct reports and / or vendor; negotiates on behalf of RA team, as necessary
  • Accountable for working with regulatory regional leads, other functions, and vendors to ensure global regulatory submissions are provided in compliance with local regulations
  • Oversee vendor responsibility for regulatory activities and submissions related to projects within scope
  • Monitor and anticipate trends that impact both the regulatory and access environments to strengthen product development plan(s) and adopt regulatory strategies in a timely manner
Desired Qualifications
  • Recent experience with a smaller entrepreneurial environment is a definite asset
  • CRO management experience preferred
Azurity Pharmaceuticals

Azurity Pharmaceuticals

View

Azurity Pharmaceuticals develops specialized formulations of existing medicines to meet the needs of patients who are often overlooked by other pharmaceutical companies. Their products include oral suspensions and other forms that are easier to take, especially for those who have trouble swallowing pills or need precise dosing. This focus on making medications more accessible helps improve patient compliance and fills gaps in the pharmaceutical market. Azurity serves healthcare providers, hospitals, and pharmacies, generating revenue through the sale of FDA-approved proprietary medicines. Their goal is to provide high-quality, innovative medicines that address unmet medical needs across various therapeutic areas, including cardiovascular, central nervous system, and oncology.

Company Size

201-500

Company Stage

Growth Equity (Venture Capital)

Total Funding

$182.2M

Headquarters

Woburn, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for personalized medicine aligns with Azurity's innovative dose forms.
  • Acquisitions enhance Azurity's R&D capabilities, accelerating new drug development.
  • FDA's focus on patient-friendly formulations supports Azurity's strategic direction.

What critics are saying

  • Zenzedi recall may harm Azurity's reputation for quality and safety.
  • Covis acquisition could lead to integration challenges and operational disruptions.
  • Azmiro launch faces competition in the testosterone replacement therapy market.

What makes Azurity Pharmaceuticals unique

  • Azurity focuses on innovative dose forms for overlooked patient needs.
  • The company offers FDA-approved proprietary medicines across diverse therapeutic areas.
  • Azurity's acquisition of Covis expands its global reach and product portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Hybrid Work Options

Professional Development Budget

Tuition Reimbursement

Wellness Program

Company News

PR Newswire
Mar 14th, 2025
Azurity Pharmaceuticals Completes Acquisition Of Covis Pharma

WOBURN, Mass., March 14, 2025 /PRNewswire/ -- Azurity Pharmaceuticals ("Azurity") announced today the successful completion of its acquisition of Covis Group S.à r.l. ("Covis") from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.This strategic acquisition reinforces Azurity's leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale.Strategic Benefits of the Acquisition:Expanded Therapeutic Portfolio – The integration of Covis' product portfolio and pipeline enhances Azurity's offerings across ten complex dosage forms and nine key therapeutic areas, including cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology.– The integration of Covis' product portfolio and pipeline enhances Azurity's offerings across ten complex dosage forms and nine key therapeutic areas, including cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology. Global Footprint – The acquisition strengthens Azurity's global footprint, expanding its commercial presence to over 50 countries and enabling greater patient accessibility to life-changing treatments. Azurity and its subsidiaries will employ more than 800 colleagues across North America , Europe and Asia.– The acquisition strengthens Azurity's global footprint, expanding its commercial presence to over 50 countries and enabling greater patient accessibility to life-changing treatments

Procurement Magazine
Mar 14th, 2025
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma

Azurity Pharmaceuticals completes acquisition of Covis Pharma.

PR Newswire
Dec 12th, 2024
Azurity Pharmaceuticals, Inc. Announces Availability Of Azmiro™ (Testosterone Cypionate) Injection For Intramuscular Use, Ciii

WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ -- Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. "Azurity's purpose is to serve overlooked patients by developing innovative dose forms and formulations to serve unmet needs," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "The commercial availability of Azmiro offers a convenient prefilled option for healthcare providers administering testosterone to patients.". Testosterone cypionate intramuscular injections are commonly used as a testosterone replacement therapy for patients with low testosterone by drawing up testosterone cypionate doses from a vial, then administering with a syringe

Eastern Progress
Dec 12th, 2024
AZURITY PHARMACEUTICALS, INC. ANNOUNCES AVAILABILITY OF AZMIRO(TM) (testosterone cypionate) injection for intramuscular use, CIII

WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ - Azurity Pharmaceuticals announced today the availability of Azmiro(TM), the first and only FDA-approved prefilled testosterone cypionate injection.

PR Newswire
May 6th, 2024
Azurity Pharmaceuticals, Inc. Announces Fda Approval Of Myhibbin™ (Mycophenolate Mofetil Oral Suspension)

WOBURN, Mass., May 6, 2024 /PRNewswire/ -- Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Myhibbin™, the only ready-to-use mycophenolate mofetil oral suspension. Mycophenolate mofetil is an antimetabolite immunosuppressant used to protect a donated organ from being rejected from the body's immune response. In 2023, there were over 46,000 transplants in the US and these patients need to take medication every day to fight against rejection. Myhibbin is indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart, or liver transplants, in combination with other immunosuppressants."We are very pleased that adult and pediatric organ transplant recipients will soon have access to the only FDA-approved ready-to-use oral liquid formulation of mycophenolate," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "Patients are our priority, and our purpose is to bring them new formulations that help them benefit from established medicines